8-K: Entera Bio Reports Q3 2025 Results, Advances Oral Peptide Pipeline

Entera Bio Ltd. announced its third quarter 2025 financial results and provided key business updates, highlighting FDA agreement on EB613's Phase 3 primary endpoint and progress across its oral peptide pipeline.

Summary

• Net loss for the three months ended September 30, 2025, was $3.2 million, or $0.07 per ordinary share, compared to a net loss of $3.0 million, or $0.08 per ordinary share, for the same period in 2024.
• Cash and cash equivalents, including restricted cash, totaled $16.6 million as of September 30, 2025, with $8.0 million specifically designated for the OPKO collaboration.
• The company anticipates its current cash resources will support operations through the middle of the third quarter of 2026.
• The FDA agreed with Entera Bio's proposal for Bone Mineral Density (BMD) as the primary endpoint for the EB613 Phase 3 study for osteoporosis.
• Phase 2 data for EB613 demonstrated significant increases in both trabecular and cortical bone indices after six months, comparable to injectable teriparatide and abaloparatide.
• New Phase 2 analysis showed EB613's ability to drive significant and consistent BMD gains in younger postmenopausal women.
• The Phase 1 trial for Next-Gen EB613 remains on track to initiate in late 2025.
• Positive preclinical data for the oral GLP-2 program (Short Bowel Syndrome) showed a plasma half-life of approximately 15 hours, an 18-fold improvement over teduglutide.
• Encouraging preclinical data for the oral OXM program (Obesity) demonstrated plasma levels consistent with the highest, 2.4 mg subcutaneous dose of Wegovy (semaglutide) weekly injection.
• An Investigational New Drug (IND) application for oral OXM is planned for the first half of 2026.
• Collaborative studies for EB612 (Hypoparathyroidism) are on track to deliver first PK/PD preclinical data by year-end 2025.

Sentiment

Score: 7

Explanation: The company reported an increased net loss and operating expenses, which are negative financial indicators. However, these are offset by significant positive clinical and regulatory advancements, including FDA agreement on a key Phase 3 endpoint for EB613, strong Phase 2 data, and promising preclinical results for pipeline candidates, which are crucial for a clinical-stage biotech. The cash runway provides stability for the near term.

Positives

• The FDA agreed on Bone Mineral Density (BMD) as the primary endpoint for EB613's Phase 3 study, a significant regulatory milestone for the oral osteoporosis treatment.
• EB613 Phase 2 data reinforced early onset of anabolism, showing significant increases in trabecular and cortical bone indices after just six months, comparable to injectable therapies.
• Expanded Phase 2 evidence for EB613 demonstrated consistent BMD gains in younger postmenopausal women, broadening the potential patient population.
• The Next-Gen EB613 Phase 1 trial is on track for initiation in late 2025, validating the N-Tab platform and potential for franchise expansion.
• The oral GLP-2 program for Short Bowel Syndrome showed positive PK data with an 18-fold improvement in plasma half-life over the only approved GLP-2 therapy, teduglutide.
• Encouraging preclinical data for the oral OXM program in obesity showed plasma levels consistent with high-dose injectable semaglutide (Wegovy).
• Cash on hand is expected to support operations through the middle of the third quarter of 2026, providing a stable runway for ongoing development.

Negatives

• Net loss increased to $3.2 million for Q3 2025, compared to $3.0 million for Q3 2024.
• Total operating expenses increased to $3.3 million for Q3 2025, up from $3.0 million in Q3 2024.
• Research and development expenses increased by $0.1 million to $1.6 million in Q3 2025, primarily due to regulatory and Phase 3 preparation activities for EB613.
• General and administrative expenses increased by $0.1 million to $1.6 million in Q3 2025.

Risks

• Changes in the interpretation of clinical data could impact regulatory outcomes.
• The results of ongoing and future clinical trials may not be favorable.
• The FDA's interpretation and review of clinical trial results and analysis could differ from the company's expectations.
• Unexpected changes in ongoing and planned preclinical development and clinical trials could occur.
• There is uncertainty regarding the timing of and the company's ability to make regulatory filings and obtain and maintain regulatory approvals for product candidates.
• Potential disruption and delay of manufacturing supply chains could impact development and commercialization.
• Loss of available workforce resources, either by Entera or its collaboration and laboratory partners, could hinder progress.
• Impacts to research and development or clinical activities that Entera may be contractually obligated to provide could arise.
• Overall regulatory timelines are subject to change and may be longer than anticipated.
• The size and growth of the potential markets for product candidates may not meet expectations.
• The scope, progress, and costs of developing Entera's product candidates could exceed current projections.
• Entera's reliance on third parties to conduct its clinical trials introduces external dependencies.
• The company's ability to establish and maintain development and commercialization collaborations is crucial for pipeline advancement.
• Operating as a development stage company with limited operating history presents inherent challenges.
• Entera faces competitive pressure from other products on the market or in development for its target disease categories.
• The company's ability to continue as a going concern is dependent on access to sources of liquidity.
• Maintaining compliance with Nasdaq's minimum listing standards and other public company requirements is ongoing.
• Protecting Entera's intellectual property position is critical for its long-term success.

Future Outlook

The company expects its current cash and cash equivalents to support operations through the middle of the third quarter of 2026. A Phase 1 trial for Next-Gen EB613 is on track to initiate in late 2025, and an Investigational New Drug (IND) application for oral OXM is planned for the first half of 2026. Collaborative studies for EB612 are expected to deliver preclinical data by year-end 2025.

Management Comments

• "Our achievements this quarter are testament to Entera's leadership position in oral peptide innovation and our team's unrelenting mission to deliver transformative treatments to patients, starting with post-menopausal women with osteoporosis."
• "Our FDA agreement for EB613 this July is unprecedented and underscores the strength of our data and the promise for EB613 to close the treatment chasm in osteoporosis, a disease which disproportionately afflicts women and remains grossly undertreated globally."

Industry Context

Entera Bio operates in the highly competitive and innovative field of oral peptide and protein replacement therapies. The focus on oral delivery for conditions like osteoporosis, short bowel syndrome, and obesity addresses a significant unmet need for less invasive alternatives to injectable treatments, potentially expanding patient access and adherence. The FDA's agreement on BMD as a primary endpoint for EB613's Phase 3 study is a notable development in osteoporosis drug development, potentially streamlining the path to market for an oral anabolic therapy. The collaboration with OPKO Health for GLP-2 and OXM programs positions Entera within the growing market for metabolic and rare disease treatments.

Comparison to Industry Standards

• EB613 Phase 2 data demonstrated significant increases in trabecular and cortical bone indices after six months, comparable to injectable teriparatide and abaloparatide, which are current anabolic treatments for osteoporosis.
• The oral GLP-2 program showed a plasma half-life of approximately 15 hours, representing an 18-fold improvement over teduglutide (Gattex), the only approved GLP-2 therapy, which requires a daily injection.
• Preclinical PK data for oral OXM showed plasma levels consistent with the highest, 2.4 mg subcutaneous dose of Wegovy (semaglutide) weekly injection, a standard of care for the treatment of obesity.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive clinical and regulatory milestones, but also increased burn rate and continued losses.
• Patients (Osteoporosis): Potential for a new, less invasive (oral) anabolic treatment option (EB613) if approved.
• Patients (Short Bowel Syndrome): Potential for a less invasive (oral) GLP-2 treatment option.
• Patients (Obesity/Metabolic Disorders): Potential for a novel oral dual GLP-1/Glucagon agonist.
• Employees: Continued employment and focus on advancing pipeline.
• OPKO Health: Continued collaboration on GLP-2 and OXM programs.

Next Steps

• Initiate Phase 3 study for EB613 (implied by FDA agreement on endpoint).
• Initiate Phase 1 trial for Next-Gen EB613 in late 2025.
• Deliver first PK/PD preclinical data for EB612 by year-end 2025.
• Plan an IND for oral OXM in H1 2026.

Key Dates

Recommendation

While the company reported an increased net loss and operating expenses, the substantial progress in its clinical pipeline, particularly the FDA's agreement on the primary endpoint for the pivotal EB613 Phase 3 study, represents a significant de-risking event and a strong positive catalyst. The promising preclinical data for other oral peptide programs (GLP-2, OXM) further validates the N-Tab platform and expands future potential. The cash runway through mid-2026 provides near-term stability. However, as a clinical-stage company with no revenue and increasing burn, future capital raises are likely, and the path to market remains long and uncertain. Therefore, a "hold" recommendation is appropriate, acknowledging the strong scientific and regulatory progress while remaining cautious about the financial profile and execution risks inherent in drug development.

Keywords

Entera Bio, ENTX, Q3 2025, Financial Results, Osteoporosis, EB613, Oral PTH(1-34), FDA Agreement, Phase 3 Study, Bone Mineral Density, Short Bowel Syndrome, GLP-2, Obesity, OXM, GLP-1, Metabolic Disorders, N-Tab Platform, Biotechnology, Pharmaceuticals, Clinical Trials, Drug Development, OPKO Health